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1. Introduction 
Disruption of the axillary nodes and closure of arm lymphatics can explain the significantly 
high risk of early and late lymphatic complications after axillary dissection, especially the 
most serious complication that is arm lymphedema which occurs in about 25% (ranging 
from 13 to 52%) of patients. Sentinel lymph node (SLN) biopsy has reduced the severity of 
swelling to  nearly 6% (from 2 to 7%) and, in case of positive SLN, complete axillary 
dissection (AD) is still required. That is why ARM method was developed aiming at 
identifying and preserve lymphatics draining the arm. It consists in injecting intradermally 
and subcutaneously a small quantity (1-2 ml) of blue dye at the medial surface of the arm 
which helps in locating the draining arm lymphatic pathways. ARM technique allowed to 
find variable clinical anatomical conditions from what was already generally known, that is 
the most common location of arm lymphatics below and around the axillary vein. In about 
one-third of the cases, blue lymphatics can be found till 3-4 cm below the vein, site where 
SLN can easily be located, justifying the occurrence of lymphedema after only SLN biopsy. 
ARM procedure showed that blue nodes were almost always placed at the lateral part of the 
axilla, under the vein and above the second intercostals brachial nerve. Leaving in place 
lymph nodes related to arm lymphatic drainage would decrease the risk of arm 
lymphedema, but not retrieving all nodes, the main risk is to leave metastatic disease in the 
axilla. Conversely, arm lymphatic pathways when they enter the axilla, cannot be site of 
breast tumoral disease and their preservation would certainly bring about a significant 
decrease of lymphedema occurrence rate (1-4). 
2. Lymphangiogenesis and other local changes 
Another important aspect to point out is that, in the axilla, new lymphatic vessel formation 
(lymphangiogenesis) occurs in response to the ligation of lymphatic vessels involved in 
lymph node retrievement. Lymphangiogenesis and lymphatic hypertension were 
demonstrated experimentally in case of lymphatic drainage obstruction. And, in response to 
lymphatic hypertension, lympho-venous shunts open and provide alternative lymphatic 
pathways when the main ones are obstructed. These mechanisms represent an adaptive 
response to lymphatic hypertension but are not enough to restore normal flow parameters. 
Furthermore, chronic obstruction to lymph flow progressively leads to a reduced lymphatic 
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contractility, lymphatic thrombosis and fibrotic changes, at a different degree according to 
variable constitutional predisposition (5-9) 
3. Surgical preventive procedures 
Recent advances in the treatment of breast cancer, specifically as concerns the prevention of 
lymphatic complications following sentinel lymph node biopsy and axillary dissection 
brought to the proposal of a new technique to primarily prevent lymphedema by 
microsurgical lymphatic-venous anastomoses. ARM technique allows to identify arm 
lymphatics and lymph nodes which can therefore be preserved even though there is the risk 
to leave undetected metastatic disease in the axilla. But, it is almost impossible to preserve 
efferent lymphatics from the blue nodes because they join the common axillary nodal basin 
draining the breast. Thus, not preserving efferent lymphatics makes practically impossible 
to preserve arm lymphatic flow. So, on the basis of our wide experience in the treatment of 
lymphedema by microsurgical lymphatic-venous anastomoses (LVA), we thought to 
perform LVA immediately after finishing nodal axillary excision. The surgical technique 
proposed for patients with operable breast cancer requiring an axillary dissection consisted 
in carrying out LVA between arm lymphatics identified by injecting blue dye in the arm and 
an axillary vein branch simultaneously (Lymphatic Microsurgical Preventive Healing 
Approach – LY.M.P.H.A.) (10). It is almost always possible to find blue lymphatics and also 
to find a vein branch long enough to be connected to arm lymphatics which are usually 
locate very laterally.  
Patients are followed up both clinically by volumetric assessment and by 
lymphangioscintigraphy performed before surgery and after 18 months. Blue nodes in 
relation to lymphatic arm drainage can be identified in almost all patients after blue dye 
injection at the arm. All blue nodes must be resected and 2 to 4 main afferent lymphatics 
from the arm can be prepared and used for anastomoses. Lymphatics are introduced inside 
the vein cut-end by a U-shaped stitch. Other few stitches are given to fix the lymphatic 
adventitia to the vein wall. The operation takes only 15-20 minutes averagely, since both 
lymphatics and the vein are prepared during nodal dissection. LVA proved not only to 
prevent lymphedema but also to reduce early lymphatic complications (i.e. lymphorrhea, 
lymphocele) thanks to the reduced regional intralymphatic pressure. Drain tubes can be 
removed after about 7-10 days at the utmost. Post-op lymphangioscintigraphy allowed to 
demonstrate the patency of microvascular anastomoses after over 1 year and half from 
operation. 
4. Clinical experience 
Study design 
Among fortynine consecutive women from March 2008 to September 2009 addressed to 
complete AD, performed by surgeons of the same Beast Unit, who used the same technique, 
46 were randomly divided in two groups, the other 3 were not analyzed because refused to 
perform lymphoscintigraphy (LS) pre-operatively. Twentythree underwent LYMPHA 
technique, performed by a surgeon skilled in lymphatic microsurgery, for the prevention of 
arm lymphedema (LYMPHA group – LG). The other 23 patients had no preventive surgical 
approach (control group – CG). No wrapping neither compression therapy was used in any 
of the patients of both groups. 
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The average age was 57 years (range 39-80 years). In order to be included in this prospective 
study, patients with unilateral breast cancer had to be addressed to complete AD due to 
clinically or ultrasonographic positive axillary limph nodes or positive SLN. Exclusion 
criteria were cases in whom only SLN biopsy technique was performed and SLNs were 
negative. 
In the LYMPHA group (LG), 16 patients there were lymph nodal metastasis and therefore 
lymphatic venous anastomosis were performed during the primary surgery together with 
breast cancer treatment, sentinel lymph node biopsy, intraoperative frozen sections 
(showing the metastasis) and axillary dissection (AD). In other 7 patients there were no 
lymph nodal metastasis demonstrated by intraoperative frozen sections and therefore 
LYMPHA technique was planned after finding micrometastasis by following 
immunohistochemical investigations. Thus, in this last group of patients we could perform 
LYMPHA during the complete lymph nodal dissection in the second time surgery. 
Operating technique 
Patients signed a specific consent form indicating the kind of operation, possible risks, and 
complications to participate or not in the LYMPHA procedure. The blue dye (Lymphazurin) 
was injected in the volar surface of the upper third of the arm in a quantity of about   1-2 ml 
intradermally, subcutaneously and under muscular fascia. Usually after 5-10 minutes it is 
already possible to visualize arm blue lymphatics. Axillary nodal dissection was performed 
usually starting far from the upper lateral part of the axilla which was removed nearly at the 
end of the dissection in order not to damage the lymphatic pathways coming from the arm. 
This lymphatics were temporally clipped near their afference to the nodal capsule and thus 
prepared for anastomosis. 
During lymph nodal dissection also one or two collateral branches of the axillary vein are 
prepared with a length suitable for reaching the lymphatic vessels. The microsurgical 
technique of lymphatic venous anastomosis has already been described (11). The vein was 
averagely 2 mm in diameter and lymphatics about half mm. the number of lymphatics 
anastomosed varied from 2 to 4. The technique is the “sleeve” procedure: lymphatics are put 
into the vein cut-end. A collateral of the axillary vein is used for anastomoses. In some cases 
a big gap inbetween the vein  and the lymphatics can be found, but in these cases it is 
usually enough to better dissect the vein and above all the lymphatics from the surrounding 
tissues. In case it is necessary one of the subscapular or thoraco-dorsal veins which are 
usually long enough can also been used. A particular attention must be paid in placing the 
drain tube in order not to damage the anastomosis (Fig.1). Lymphatic-venous anastomoses 
take only 15-20 minutes to be performed and in our study were performed by a surgeon 
skilled in lymphatic microsurgery. There is no increased rate of blood loss, wound infection 
and seromas compared to standard ALND (Fig. 2). 
Clinical and lymphoscintigraphic assessment 
All patients of the two groups were preoperatively studied clinically by volume 
measurements (using the formula of a truncated cone according to Kuhnke method) (10) 
and by lymphoscintigraphy. Lymphedema, was defined as a difference in excess volume of 
at least 100 ml compared to preoperative VOL  measurements. The follow up included 
volumetry at 1, 3, 6, 12 and 18 months postoperatively in  both groups. 
Lymphoscintigraphy was carried out in 21 cases in the LG and in 20 cases of the CG after 18 
months postoperatively (Fig. 3). 
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Fig. 1. Lymphatic-venous-anastomoses (rectangle) to prevent arm lymphedema (LYMPHA). 
Note the blue dye (*) injected at the upper third of the volar surface of the arm to visualise 
arm lymphatics. The patency of lymphatic-venous anastomosis is proved by the passage of 
the blue dye into the vein branch (arrow). 
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Fig. 2. Patient who underwent axillary lymphnodal dissection and primary surgical 
prevention of secondary lymphedema by LYMPHA procedure.  
Statistical analysis  
Non-parametric tests were used to explore the variable relationships between groups and 
between timing. The comparison between groups of quantitative variables age, BMI, Preop 
LS, lymphonodes retrived, metastatic lymphnodes (MLS LN) and volume at baseline was 
performed using Wilcoxon test. Nominal baseline variables surgical procedure, 
radiotherapy and presence of cellulitis were compared using Chi square or Fisher’s Exact 
Test. 
The comparison of difference between baseline and volume after 1, 3, 6, 12 and 18 months 
from operation in LG and CG was performed using Wilcoxon test (between groups) and 
matched pair test (between timing). The volume difference between baseline and different 
timing in LG and CG was represented by box plots showing 10°, 25°, 75° and 90° percentiles. 
Number of patients with lymphedema, defined as a difference in excess volume of at least 
100 ml, at 18 months in PG and CG were compared using 2-sided Fischer’s Exact Test. 
Results 
Lymphedema appeared in 1 patient in the LG after 6 months from the operation (4,34 %) 
and persisted till 18 months later. It occurred in a patient who underwent radiotherapy and 
became stable with time without any inflammatory complications. In the CG lymphedema 
occurred in 7 patients (30,43 %) and appeared mostly after 3 months from operation. 
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Beginning from month 3, the proportion of patients with lymphedema was statistically 
higher in CG (p-value=0.047). Table 1 summarizes baseline characteristics of all participants, 
according to treatment group. There were no significant differences between the two groups 
in the baseline values of measures of demographic and anthropometric data, in disease 
characteristics and in type of surgery, and in the proportion of women who undertook to 
radiotherapy and had a cellulitis. In Figure 4, volume difference between baseline and 
different timing in LG and CG is represented by box plots showing 10°, 25°, 75° and 90° 
percentiles. 
When compared with previous volume measure, no significant difference in the arm 
volume were observed in LG during follow-up, while the arm volume in CG showed a 
significant increase after 1 (mean difference 11.61 ml, S.E. 3.87, p-value<0.01) , 3 (mean 
difference 22.82 ml, S.E. 5.9, p-value<0.01) and 6 months (mean difference 31.56 ml, S.E. 5.78, 
p-value<0.01) from operation. No significant changes in arm volume were observed at 
month 12 and 18, in comparison with data registered at month 6 and 12, respectively, in CG. 
Significant higher volume with respect to baseline after 1, 3, 6, 12 and 18 months from 
operation (every timing p-value<0.01) was detected in CG in comparison with LG.  
 
 
 
 
Fig. 3. Lymphoscintigraphic patterns before and after axillary lymphnodal dissection 
associated with LYMPHA technique.  
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Duplex scan allowed to exclude a venous pathology in all patients. LS allowed to confirm 
the lymphostatic nature of the edema. To quantify visual  findings in LS, the Kleinhans 
transport index (TI) was used (4,13,14). The TI  includes the following parameters: transport 
kinetics (K), distribution of the tracer (D),  appearance time of lymph nodes in minutes (T), 
visualization of lymph nodes (N), visualisation of lymph vessels (V); TI = K + D + (0,04 x T) 
+ N + V (Table 2). Normal lymphoscintigraphy pattern corresponded to TI less than 10. An 
impaired LS pattern in our study had a mean TI of 16 (range 12-19). 
Moreover, pre-operatively LS had a significant predictive value (TI) in terms of risk of  
lymphedema appearance. To this regard LS proved to be an instrumental criteria to select 
patients at risk for secondary lymphedema. 
Post-operatively LS demonstrated the patency of microlymphaticvenous anastomosis 
(patency rate: 95,6%) both through direct (visualization of preferential lymphatic pathway, 
disappearance of the tracer passing into the blood stream) and indirect (early liver uptake of 
the tracer) parameters in the LG group.  In the CG on the other hand LS allowed to point out 
lymphatic drainage impairment in patients with secondary lymphedema. 
5. Discussion 
Notwithstanding the wide variability in lymphedema prevalence, the incidence of 
secondary arm lymphedema is significant. Sentinel lymph node biopsy (SLNB) was 
introduced and carried out to prevent lymphedema but, recent studies demonstrated that 
even with SLNB alone lymphedema rates are not negligible (13,17). 
Therefore, prevention is of key importance to avoid lymphedema occurrence.  
Axillary Reverse Mapping (ARM) procedure represents an attempt to identify and preserve 
arm lymphatic drainage. Success of this technique in preventing lymphedema will require 
ongoing follow-up and studies (6).  Blue nodes were always located in the same position, at 
the lateral part of the dissection, under the axillary vein and just above the second 
intercostal brachial nerve (7). The main issue remains to make sure that the nodes identified 
are not metastatic and can be preserved during AD. Since the lymphatic pathways from the 
arm cannot be involved by metastatic process of the primary breast tumor, its preservation 
should not imply any risk of leaving undetected diseases in the axilla (1). With ARM 
technique the detection rate of blue lymphatics and nodes is 61-71%, and the preservation 
rate of 47% (1,6,7). The question is: can we spare what we find? The identification of afferent 
lymphatics and nodes belonging to the arm lymphatic pathways appears feasible. 
Nevertheless, the identification of the efferent lymphatics, which is mandatory to truly 
preserve the lymphatic flow of the arm, is almost impossible since the lymphatics departing 
from the blue nodes join the common lymphatic pathways draining the breast. Therefore, 
the preservation is practically impossible. That’s why we conceived and carried out 
LYMPHA technique, which consist in performing LVA between arm lymphatics and 
collateral branches of the axillary vein at the same time as AD. Lymphatic-venous 
anastomoses are performed at the upper lateral part of the axilla, thus somehow protected 
from the negative effect of postop radiation. In fact, postop radiation did not cause any 
relevant problem in the patients with lymphatic-venous anastomoses in this study. Only in 
two patients, a transitory (for 3 and 5 days respectively) slight arm edema was observed 
which disappeared spontaneously. Patients were followed by volume measurements which 
allowed to demonstrate the absence of any negative effect of postop radiation. Furthermore, 
postop lymphoscintigraphy proved the patency of anastomoses long after surgery and 
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radiation. The preservation of arm lymphatics carries no risk of leaving disease in the axilla 
undetected, and it permits the prevention of lymphedema (10). Patients candidate for 
LYMPHA are those one addressed to AD with either clinical axillary N+ or SLN+. In pre-
operative patients selection for LYMPHA clinical and instrumental criteria were evaluated 
(Fig.4).  
 
 
Fig. 4. Clinical and instrumental criteria to select patients for LYMPHA technique 
History and physical esamination of the patients, together with BMI, could allow to select 
patients at risk for lymphedema and this suspect could be confirmed by LS, using 
semiquantitative evaluation which is represented by TI (15-19). Preop 
lymphoscintigraphy is useful to select patients at risk for arm lymphedema. LS  shows 
lymphatic impairment (in terms of transport index) compared to the contralateral arm 
already present pre-operatively. 
The quality of life is gaining more and more importance thanks to the prolongation of 
survival brought about by advanced and combined treatment of different tumors. Surgery 
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has to be more and more conservative and try to maintain organ function and reduce 
morbility. LYMPHA technique proved to represent a new strategy of treatment to reduce 
morbility of axillary lymph nodal dissection when it is not possible to preserve arm 
lymphatic pathways due to the risk to leave tumoral diseases correlated to the breast cancer.  
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